IQVIA Holdings Inc. $IQV Shares Purchased by UniSuper Management Pty Ltd

UniSuper Management Pty Ltd raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.1% during the first quarter, Holdings Channel.com reports. The institutional investor owned 16,654 shares of the medical research company’s stock after buying an additional 500 shares during the period. UniSuper Management Pty Ltd’s holdings in IQVIA were worth $2,936,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. American National Bank & Trust acquired a new stake in shares of IQVIA during the first quarter worth $26,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of IQVIA by 436.7% during the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after purchasing an additional 131 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new stake in shares of IQVIA during the first quarter worth $33,000. Finally, ST Germain D J Co. Inc. boosted its holdings in shares of IQVIA by 66.1% during the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider directly owned 2,910 shares of the company’s stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on the company. Mizuho raised their price objective on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Evercore ISI raised their price objective on IQVIA from $170.00 to $180.00 and gave the stock an “outperform” rating in a report on Wednesday, July 9th. Truist Financial raised their price objective on IQVIA from $209.00 to $235.00 and gave the stock a “buy” rating in a report on Wednesday, July 23rd. JPMorgan Chase & Co. reduced their target price on IQVIA from $232.00 to $177.00 and set an “overweight” rating on the stock in a report on Monday, May 19th. Finally, UBS Group lifted their target price on IQVIA from $185.00 to $225.00 and gave the company a “buy” rating in a report on Wednesday, July 23rd. Eighteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $229.64.

IQVIA Price Performance

Shares of IQVIA stock opened at $189.89 on Wednesday. The business’s fifty day moving average price is $181.03 and its 200 day moving average price is $167.36. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $248.03. The stock has a market capitalization of $32.28 billion, a P/E ratio of 27.48, a PEG ratio of 2.06 and a beta of 1.32.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period last year, the company posted $2.64 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.